2018 Press Releases

Keyword Search
 
June 7, 2018
Iovance Biotherapeutics Announces First Patient Dosed in Europe for Ongoing C-144-01 Phase 2 Trials in Metastatic Melanoma
SAN CARLOS, Calif., June 07, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, today announced that the first patient was dosed in the ongoing C-144-01 Phase 2 trial of LN-144 (lifileucel) for the treatment of patients with metastatic melanoma at a clinical trial site in the United Kingdom.  “The dosing of the first patient with lifileucel in Europe fo... More »
May 31, 2018
Iovance Biotherapeutics to Present at Two Investor Conferences in June
SAN CARLOS, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in June: Jefferies 2018 Global Healthcare Conference in New York, NY on Thursday, June 7, 2018 at 9:00 a.m. ET JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 20... More »
May 10, 2018
Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
- Company to Host Conference Call at 4:30pm ET Today - SAN CARLOS, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its first quarter 2018 financial results and provided a corporate update. “Our January 2018 financing puts us in a strong position to advance and expand our robust TIL product pipeline. We continue enrollm... More »
May 3, 2018
Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018
SAN CARLOS, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2018 financial and operating results on Thursday, May 10, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. In order to participate... More »
May 2, 2018
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May
SAN CARLOS, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in May: Deutsche Bank’s 43rd Annual Health Care Conference in Boston, MA on Tuesday, May 8, 2018 at 2:50 p.m. ET UBS Global Healthcare Conference in New York, NY on Monday, May 21, 2018 at... More »
March 12, 2018
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
Company to Host Conference Call at 4:30pm ET Today SAN CARLOS, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its fourth quarter and year-end 2017 financial results and provided a corporate update. “We ended 2017 having completed significant accomplishments involving both manufacturing and clinical aspects of developm... More »
March 8, 2018
Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018
SAN CARLOS, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its fourth quarter and year-end 2017 financial and operating results after the close of the U.S. financial markets on Monday, March 12, 2018. Management will host a conference call and live audio webcast to discuss these results and provide ... More »
March 7, 2018
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March
SAN CARLOS, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in March: Cowen 38th Annual Health Care Conference in Boston, MA on Wednesday, March 14, 2018 at 10:40 a.m. ET Oppenheimer’s 28th Annual Healthcare Conference in New York, NY on Wednesday,... More »
March 1, 2018
Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors
Industry Veteran Brings Significant Clinical, Commercial, and Business Experience SAN CARLOS, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Michael Weiser, M.D., Ph.D., to Iovance’s Board of Directors, effective March 15, 2018.  Dr. Weiser will serve as the chair of Iovance’s Compensation Committee... More »
February 14, 2018
Iovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
SAN CARLOS, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will present a corporate overview at the upcoming RBC Capital Markets 2018 Global Healthcare Conference on Thursday, February 22, 2018 at 2:35 p.m. ET in New York, NY. A live audio webcast of the presentation will be available by visiting the... More »
January 29, 2018
Iovance Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock Public Offering
SAN CARLOS, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the closing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $11.50 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering... More »
January 25, 2018
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
SAN CARLOS, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the pricing of an underwritten public offering of 13,043,479 shares of its common stock at a public offering price of $11.50 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering... More »
January 24, 2018
Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock
SAN CARLOS, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it intends to offer and sell $125 million of its common stock, subject to market and other conditions, in an underwritten public offering. All of the shares in the offering are to be sold by Iovance. Iovance intends to grant the underwriters a 30-day option... More »
January 24, 2018
Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers
Three of Eight Evaluable Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with LN-145 Experienced a Confirmed Partial Response                   One of Two Evaluable Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma Treated with LN-145 Experienced a Confirmed Partial Response SAN CARLOS, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer... More »